These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2655098)

  • 21. Clinical application of oxaliplatin in epithelial ovarian cancer.
    Fu S; Kavanagh JJ; Hu W; Bast RC
    Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin.
    Muggia FM
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):7-13. PubMed ID: 2655099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin.
    Gutierrez M; Pautier P; Lhommé C
    J Clin Oncol; 2002 Jan; 20(1):353. PubMed ID: 11773195
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian trials at the Royal Marsden.
    Wiltshaw E
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():67-71. PubMed ID: 3910224
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.
    Fish RG; Shelley MD; Maughan T; Rocker I; Adams M
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):831-5. PubMed ID: 3308479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin: the clinical spectrum to date.
    Canetta R; Rozencweig M; Carter SK
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():125-36. PubMed ID: 3002623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin in the treatment of ovarian cancer.
    Alberts DS; Mason-Liddil N
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin: the clinical evaluation strategy.
    Rozencweig M; Canetta R; Carter SK
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():137-44. PubMed ID: 3910217
    [No Abstract]   [Full Text] [Related]  

  • 32. [Phase III study of carboplatin in ovarian cancer].
    Kato T; Nishimura H; Yamabe T; Terashima Y; Kasamatsu T; Hirabayashi K; Nishiya I; Yajima A; Takamizawa H; Tsutsui F
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2297-304. PubMed ID: 3044276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer.
    Rothenberg ML; Ostchega Y; Steinberg SM; Young RC; Hummel S; Ozols RF
    J Natl Cancer Inst; 1988 Nov; 80(18):1488-92. PubMed ID: 2846858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
    Kavanagh JJ; Edwards CL; Freedman RS; Finnegan MB; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin JL
    Gynecol Oncol; 1995 Jul; 58(1):106-9. PubMed ID: 7789874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin: the experience in head and neck cancer.
    Eisenberger M; Van Echo D; Aisner J
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):34-41. PubMed ID: 2655096
    [No Abstract]   [Full Text] [Related]  

  • 36. Whither carboplatin? A replacement for or an alternative to cisplatin?
    Gil A
    J Clin Oncol; 1987 Dec; 5(12):2041-2. PubMed ID: 3316520
    [No Abstract]   [Full Text] [Related]  

  • 37. Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
    Markman M
    Gynecol Oncol; 1999 Jun; 73(3):469-70; author reply 470-2. PubMed ID: 10366485
    [No Abstract]   [Full Text] [Related]  

  • 38. JMS, successor to cisplatin in advanced ovarian carcinoma?
    Wiltshaw E; Evans BD; Jones AC; Baker JW; Calvert AH
    Lancet; 1983 Mar; 1(8324):587. PubMed ID: 6131277
    [No Abstract]   [Full Text] [Related]  

  • 39. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
    Piccart MJ; Green JA; Lacave AJ; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez CM; Curran D; Van Glabbeke M; Lacombe D; Pinel MC; Pecorelli S
    J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group.
    Wiltshaw E; Perren TJ; Fryatt ID; Blake PR; Harper P; Slevin M
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S48-50. PubMed ID: 2189595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.